Hesperetin, Liver Fibrosis, Gut Microbiota and Autophagy

Hesperetin, a naturally occurring flavonoid with notable anti-inflammatory and antioxidant properties, has shown promising effects in addressing liver fibrosis, a condition characterized by excessive scarring due to chronic liver injury. In a mouse model of carbon tetrachloride-induced liver fibrosis, hesperetin demonstrated significant antifibrotic potential. It reduced liver injury and fibrosis, improved liver tissue structure, and suppressed autophagy-related markers in hepatic stellate cells, which are key drivers of fibrosis. By inhibiting the activation of these cells, hesperetin effectively limited the progression of fibrosis and decreased inflammatory cell infiltration within the liver.

Additionally, hesperetin influenced gut microbiota composition, an important factor in liver health. Using 16S rDNA sequencing, researchers observed that hesperetin increased the proportion of Firmicutes and boosted beneficial populations of lactic acid bacteria. These changes in gut microbial balance contributed to reduced liver inflammation and fibrosis, highlighting the gut-liver axis's role in disease modulation.

The study concluded that hesperetin alleviates liver fibrosis through a multifaceted mechanism involving the suppression of hepatic stellate cell autophagy, reduction of inflammation, and restoration of healthy gut microbiota. These findings suggest hesperetin as a potential therapeutic candidate for managing liver fibrosis and improving overall liver health.